Skip to main content
Erschienen in: International Journal of Legal Medicine 1/2019

29.06.2018 | Case Report

Mass poisoning with NPS: 2C-E and Bromo-DragonFly

verfasst von: S. Iwersen-Bergmann, S. Lehmann, A. Heinemann, C. Schröder, A. Müller, H. Jungen, H. Andresen-Streichert, K. Pueschel, C. Vidal, K. Mercer-Chalmers-Bender

Erschienen in: International Journal of Legal Medicine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Reports of intoxications with new psychoactive substances (NPS) mostly involve young people, as they are the main consumers of these types of drugs. This report centers on a case that was unusual due to it being a mass-poisoning event involving middle-aged individuals who had consumed a combination of the two different new psychoactive drugs 2,5-dimethoxy-4-ethylphenethylamine (2C-E) and 1-(8-bromofuro[2,3-f][1]benzofuran-4-yl)-2-propanamine (Bromo-DragonFly, BDF).

Case history

The mass poisoning of 29 individuals (24–56 years old) resulted in their admission to six different hospitals with severe symptoms of intoxication. All symptoms manifested after consumption of an unknown drug formulation around lunchtime during an esoteric weekend seminar.

Investigation

Urine (n = 11) and blood samples (n = 29), collected from the 29 individuals for police investigation, were analyzed with immunochemical techniques, GC/MS and LC-MS/MS. 2C-E was confirmed in seven urine samples, but not in blood. BDF was confirmed in all urine samples, and in 17 blood samples. The blood samples exhibited BDF concentrations between ca. 0.6 and ca. 2.0 μg/L, while urine concentrations of BDF ranged from ca. 1.6 to 35 μg/L. The concentration of 2C-E in urine was found to be between ca. 1.5 and 183 μg/L. All patients made a complete recovery, although some had required mechanical ventilation.

Conclusion

The investigation and the presentation of this case illustrates not only mass intoxication with 2C-E and BDF, with corresponding blood and urine concentrations, but also the necessity of collecting urine samples in cases where NPS-consumption is suspected, in order to improve the chances of analytical detection.
Literatur
1.
Zurück zum Zitat Musselman ME, Hampton JP (2014) “Not for human consumption”: a review of emerging designer drugs. Pharmacotherapy 34:745–757CrossRefPubMed Musselman ME, Hampton JP (2014) “Not for human consumption”: a review of emerging designer drugs. Pharmacotherapy 34:745–757CrossRefPubMed
2.
Zurück zum Zitat Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2014) 2C or not 2C: phenylethylamine designer drug review. J Med Toxicol 9:172–178CrossRef Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2014) 2C or not 2C: phenylethylamine designer drug review. J Med Toxicol 9:172–178CrossRef
3.
Zurück zum Zitat Shulgin AT, Shulgin A (1991) PIHKAL: a chemical love story. Transform Press, Berkeley Shulgin AT, Shulgin A (1991) PIHKAL: a chemical love story. Transform Press, Berkeley
4.
Zurück zum Zitat Betäubungsmittelgesetz in der Fassung der Bekanntmachung vom 1. März 1994 (BGBl. I S. 358), das zuletzt durch Artikel 1 der Verordnung vom 16. Juni 2017 (BGBl. I S. 1670) geändert worden ist Betäubungsmittelgesetz in der Fassung der Bekanntmachung vom 1. März 1994 (BGBl. I S. 358), das zuletzt durch Artikel 1 der Verordnung vom 16. Juni 2017 (BGBl. I S. 1670) geändert worden ist
5.
Zurück zum Zitat Van Vranken MJ, Benavides R, Wians FH (2013) Identification of designer drug 2C-E (4-ethyl-2, 5-dimethoxy-phenethylamine) in urine following a drug overdose. Proc (Bayl Univ Med Cent) 26(1): 58–61B Van Vranken MJ, Benavides R, Wians FH (2013) Identification of designer drug 2C-E (4-ethyl-2, 5-dimethoxy-phenethylamine) in urine following a drug overdose. Proc (Bayl Univ Med Cent) 26(1): 58–61B
6.
Zurück zum Zitat Topeff JM (2011) The use of intravenous fat emulsion as an adjunct to standard ACLS in the resuscitation of a patient in cardiopulmonary arrest after 2C-E use. Clin Tox 49(6):541 Topeff JM (2011) The use of intravenous fat emulsion as an adjunct to standard ACLS in the resuscitation of a patient in cardiopulmonary arrest after 2C-E use. Clin Tox 49(6):541
7.
Zurück zum Zitat Topeff JM, Ellsworth H, Willhite LA, Bangh SA, Edwards EM, Cole JB (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Tox 49:526 Topeff JM, Ellsworth H, Willhite LA, Bangh SA, Edwards EM, Cole JB (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Tox 49:526
8.
Zurück zum Zitat Andreasen MF, Telving R, Birkler RID, Schumacher B, Johannsen M (2009) A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int 183:91–96CrossRefPubMed Andreasen MF, Telving R, Birkler RID, Schumacher B, Johannsen M (2009) A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int 183:91–96CrossRefPubMed
9.
Zurück zum Zitat Corazza O, Schifano F, Farre M, Deluca P, Davey Z, Torrens M, Demetrovics Z, Di Furia L, Flesland L, Siemann H, Skutle A, Van Der Kreeft P, Scherbaum N (2011) Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 6:125–129CrossRefPubMed Corazza O, Schifano F, Farre M, Deluca P, Davey Z, Torrens M, Demetrovics Z, Di Furia L, Flesland L, Siemann H, Skutle A, Van Der Kreeft P, Scherbaum N (2011) Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 6:125–129CrossRefPubMed
10.
Zurück zum Zitat Wood DM, Looker JJ, Shaikh L, Button PJM, Davies S, Lidder S, Ramsey J, Holt DW, Dargan PI (2009) Delayed onset of seizures and toxicity associated with recreational use of Bromo-DragonFLY. J Med Toxicol 5:226–229CrossRefPubMedPubMedCentral Wood DM, Looker JJ, Shaikh L, Button PJM, Davies S, Lidder S, Ramsey J, Holt DW, Dargan PI (2009) Delayed onset of seizures and toxicity associated with recreational use of Bromo-DragonFLY. J Med Toxicol 5:226–229CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE (1998) A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem 17:5148–5149CrossRef Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE (1998) A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem 17:5148–5149CrossRef
12.
Zurück zum Zitat Hill SL, Thomas SHL (2011) Clinical toxicology of newer recreational drugs. Clin Tox 49:705–771CrossRef Hill SL, Thomas SHL (2011) Clinical toxicology of newer recreational drugs. Clin Tox 49:705–771CrossRef
14.
Zurück zum Zitat Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE (2001) Enatiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists. J Med Chem 44:1003–1010CrossRefPubMed Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE (2001) Enatiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists. J Med Chem 44:1003–1010CrossRefPubMed
15.
Zurück zum Zitat Neues-psychoaktive-Stoffe-Gesetz (NpSG), 26.11.2016 Neues-psychoaktive-Stoffe-Gesetz (NpSG), 26.11.2016
16.
Zurück zum Zitat Maurer HH, Pfleger K, Weber A (2011) Mass spectral library and GC data of drugs, poisons, pesticides, pollutants, and their metabolites. Hoboken, Ney Jersey, USA: Wiley-VCH, GmbH Maurer HH, Pfleger K, Weber A (2011) Mass spectral library and GC data of drugs, poisons, pesticides, pollutants, and their metabolites. Hoboken, Ney Jersey, USA: Wiley-VCH, GmbH
17.
Zurück zum Zitat Rösner P (2012) Mass spectra of designer drugs. Wiley-VCH Rösner P (2012) Mass spectra of designer drugs. Wiley-VCH
18.
Zurück zum Zitat Lehmann S, Kieliba T, Beike J, Thevis M, Mercer-Chalmers-Bender K (2017) Determination of 74 new psychoactive substances in serum using automated in-line solid-phase extraction-liquid chromatography-tandem mass spectrometry. J Chromatogr B 1064:124–138CrossRef Lehmann S, Kieliba T, Beike J, Thevis M, Mercer-Chalmers-Bender K (2017) Determination of 74 new psychoactive substances in serum using automated in-line solid-phase extraction-liquid chromatography-tandem mass spectrometry. J Chromatogr B 1064:124–138CrossRef
19.
Zurück zum Zitat Peters FT, Hartung M, Herbold M, Schmitt G (2009) Guidelines for quality assurance in forensic-toxicological analyses. Richtlinie der GTFCh zur Qualitätssicherung bei Forensisch Toxikologischen Untersuchungen Anhang B. Toxichem Krimtech 76:185–208 Peters FT, Hartung M, Herbold M, Schmitt G (2009) Guidelines for quality assurance in forensic-toxicological analyses. Richtlinie der GTFCh zur Qualitätssicherung bei Forensisch Toxikologischen Untersuchungen Anhang B. Toxichem Krimtech 76:185–208
21.
Zurück zum Zitat Thorlacius K, Borna C, Personne M (2008) Bromo-dragon fly-life-threatening drug. Can cause tissue necrosis as demonstrated by the first described case. Lakartidningen 105(16):1199–1200PubMed Thorlacius K, Borna C, Personne M (2008) Bromo-dragon fly-life-threatening drug. Can cause tissue necrosis as demonstrated by the first described case. Lakartidningen 105(16):1199–1200PubMed
22.
Zurück zum Zitat Peronne M, Hulten P (2008) Bromo-Dragonfly, a life threatening designer drug. Clin Toxicol 46:379 Peronne M, Hulten P (2008) Bromo-Dragonfly, a life threatening designer drug. Clin Toxicol 46:379
23.
Zurück zum Zitat Bronstein AC, Spyker DA, Cantilena LR (2010) Annual report of the American Association of Poison Control Centers` National Poison Data System (NPDS: 27th annual report). Clin Tox 48:1175CrossRef Bronstein AC, Spyker DA, Cantilena LR (2010) Annual report of the American Association of Poison Control Centers` National Poison Data System (NPDS: 27th annual report). Clin Tox 48:1175CrossRef
24.
Zurück zum Zitat Haroz R, Greenberg MI (2006) New drugs of abuse in North America. Clin Lab Med 26(147–64):ix Haroz R, Greenberg MI (2006) New drugs of abuse in North America. Clin Lab Med 26(147–64):ix
25.
Zurück zum Zitat Rohanová M, Pálenícek T, Balíková M (2008) Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. Toxicol Lett 21;178:29–36 Rohanová M, Pálenícek T, Balíková M (2008) Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. Toxicol Lett 21;178:29–36
26.
Zurück zum Zitat Spiegel D (2017) Das dritte Auge 26:58–60 Spiegel D (2017) Das dritte Auge 26:58–60
Metadaten
Titel
Mass poisoning with NPS: 2C-E and Bromo-DragonFly
verfasst von
S. Iwersen-Bergmann
S. Lehmann
A. Heinemann
C. Schröder
A. Müller
H. Jungen
H. Andresen-Streichert
K. Pueschel
C. Vidal
K. Mercer-Chalmers-Bender
Publikationsdatum
29.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Legal Medicine / Ausgabe 1/2019
Print ISSN: 0937-9827
Elektronische ISSN: 1437-1596
DOI
https://doi.org/10.1007/s00414-018-1882-9

Weitere Artikel der Ausgabe 1/2019

International Journal of Legal Medicine 1/2019 Zur Ausgabe

Neu im Fachgebiet Rechtsmedizin